Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Fineline Cube Aug 3, 2026
Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Fineline Cube Aug 3, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Fineline Cube Aug 3, 2026
Company Deals

ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline

Fineline Cube Jan 16, 2023

ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions”...

Company Drug

Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder

Fineline Cube Jan 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...

Company

WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference

Fineline Cube Jan 16, 2023

China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...

Company Drug

Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA

Fineline Cube Jan 16, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Company Deals

ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion

Fineline Cube Jan 16, 2023

Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of...

Company Drug

Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication

Fineline Cube Jan 16, 2023

China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...

Company Drug

Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023

Fineline Cube Jan 16, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization...

Company Drug

Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment

Fineline Cube Jan 16, 2023

Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...

Company Deals

JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline

Fineline Cube Jan 16, 2023

Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million)...

Company Drug

Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE

Fineline Cube Jan 16, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...

Company Deals

Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China

Fineline Cube Jan 16, 2023

China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...

Company Drug

Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038

Fineline Cube Jan 16, 2023

Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...

Company Deals

Eyougene Raises Hundreds of Millions in Series B Funding for Expansion

Fineline Cube Jan 13, 2023

Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has...

Company Deals

LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions”...

Company Deals

Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has...

Company Drug

Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study

Fineline Cube Jan 13, 2023

China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...

Company Deals

Cii Tech Secures Tens of Millions in Pre-Series A Funding for Mass Spectrometry

Fineline Cube Jan 13, 2023

China Innovation Instrument (Cii Tech), a life sciences instrument maker based in Ningbo, has reportedly...

Company Deals

TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline

Fineline Cube Jan 13, 2023

TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of...

Company Drug

Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma

Fineline Cube Jan 13, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...

Company Drug

Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study

Fineline Cube Jan 13, 2023

Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...

Posts pagination

1 … 609 610 611 … 702

Recent updates

  • BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway
  • China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions
  • Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab
  • AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Company Drug

Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.